Clinical Trial Update: The Efficacy of Prophylactic TAF for HBsAg-positive Patients Receiving bDMARDs [Phase 4]

View source ↗

Summary

Clinical trial update reporting on prophylactic TAF for HBsAg-positive patients receiving biological DMARDs in inflammatory arthritis (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Inflammatory Arthritis

Drugs mentioned

• TAF (tenofovir alafenamide)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: HBV, Inflammatory Arthritis | Phase 4 | Status: UNKNOWN